GLIMIFIX is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with non insulin-dependent (Type 2) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone. GLIMIFIX may be used concomitantly with metformin when diet, exercise, and glimepiride or metformin alone do not result in adequate glycaemic control. GLIMIFIX is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycaemic agent. Combined use of glimepiride and insulin may increase the potential for hypoglycaemia.

General

Dosage should be individualized on the basis of both effectiveness and tolerance. There is no fixed dosage regimen for the management of diabetes mellitus with glimepiride or any other hypoglycaemic agent.

Usual Starting Dose

The usual starting dose of GLIMIFIX as initial therapy is 1-2 mg once daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycaemic drugs should be started at 1 mg once daily, and should be titrated carefully. 
No exact dosage relationship exists between glimepiride and the other oral hypoglycaemic agents. The maximum starting dose of GLIMIFIX should be no more than 2 mg.
Failure to follow an appropriate dosage regimen may precipitate hypoglycaemia. Patients who do not adhere to their prescribed dietary and drug regimen are more prone to exhibit unsatisfactory response to therapy.